ReviewAmerican journal of clinical and experimental urology2014
Estrogen receptors in prostate development and cancer.
Review in American journal of clinical and experimental urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 31 citations in OpenAlex.
- Stachydrine hydrochloride induces cell senescence and ferroptosis of castration-resistant prostate cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- State-of-the-art therapeutic strategies for targeting cancer stem cells in prostate cancer.Frontiers in oncology · 2023Review
- Transcription Factors as Novel Therapeutic Targets and Drivers of Prostate Cancer Progression.Frontiers in oncology · 2022Review
- Estrogen Biosynthesis and Signal Transduction in Ovarian Disease.Frontiers in endocrinology · 2022Review
- Random forest-based modelling to detect biomarkers for prostate cancer progression.Clinical epigenetics · 2019Article
- Review
- Estrogen receptor α-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer.Cell communication and signaling : CCS · 2019Article
- Estrogens and prostate cancer.Prostate cancer and prostatic diseases · 2019Review
- Angiotensin 1-7 modulates molecular and cellular processes central to the pathogenesis of prostate cancer.Scientific reports · 2018Article
- Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis.World journal of gastroenterology · 2017Article
- CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer.Cancer research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is an androgen-sensitive disease, which can be pharmacologically controlled by androgen blockade. To date, a growing body of evidence showed that estrogen and estrogen receptors (ERs) could regulate prostate development, as well as cancer initiation and progression. This review will address the expression levels and function of ERs in different stages of PCa progression. The functions of ERs in different types of prostate cells, the ligand effect, and the potential applications of selective estrogen modulators (SERMs) will also be discussed. To further dissect ERs' roles in prostate development, cell type specific ER knockout mouse models were generated. Results collected from the prostate cell type-specific ERαKO mouse models provided new insights about the cell type specific ERα roles in prostate development prenatally and postnatally. The results of ERs' roles in mouse PCa mode and the correlation of ERs expression and biomedical outcome will also be discussed.
Indexed as
Identifiers
25374919PMC4219301W190869976What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.